 | Up a level |
2015
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Azarnia, N., Petrone, M. E., Snyder, B. R., Maniar, M. and Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leuk. Res., 39. S. S57 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Azarnia, N., Petrone, M. E., Snyder, B. R., Maniar, M. and Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leuk. Res., 39. S. S57 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835